Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/12/2019
SIETES contiene 92850 citas

 
 
<< anterior 21 a 40 de 167 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Godlee F. Withdraw approval for Tamiflu until NICE has full data. BMJ 2012;345:27. [Ref.ID 94247]
22. Cita con resumen
Kesselheim AS, Avorn J, Greene JA. Risk, responsibility, and generic drugs. N Engl J Med 2012;367:1679-81. [Ref.ID 93957]
23. Cita con resumen
Anónimo. Getting the timing right. Drug Ther Bull 2012;50:13. [Ref.ID 92424]
24.Enlace a cita original Cita con resumen
Anónimo. Statin drugs - Drug safety communication: class labeling change. U.S. Food and Drug Administration 2012:1 de marzo. [Ref.ID 92196]
25. Cita con resumen
Egan A, Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med 2011;365:285-7. [Ref.ID 90930]
26.Tiene citas relacionadas
D'Amico AV. Risk-based management of prostate cancer. N Engl J Med 2011;365:169-71. [Ref.ID 90833]
27.Tiene citas relacionadas Cita con resumen
Theoret MR, Ning Y-M, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5a-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011;365:97-9. [Ref.ID 90829]
28. Cita con resumen
Carpenter D, Kesselheim AS, Joffe S. Reputation and precedent in the bevacizumab decision. N Engl J Med 2011;365:e3. [Ref.ID 90772]
29.Enlace a cita original
Anónimo. Chantix (varenicline): Label change - Risk of certain cardiovascular adverse events. FDA Drug Bull 2011:20 junio. [Ref.ID 90765]
30. Cita con resumen
Anónimo. Nabiximoles. Sativex (Almirall). PAM 2011;35:259-66. [Ref.ID 90584]
32.
Fitzgerald JM, Quon BS. The impact of asthma guidelines. Lancet 2010;376:751-3. [Ref.ID 89308]
33. Cita con resumen
Beasley R, Perrin K, Weathreall M, Wijesinghe M. Call for withdrawal of LABA single-therapy inhaler in asthma. Lancet 2010;376:750-1. [Ref.ID 89307]
34.
Anónimo. Proton Pump Inhibitors (PPI): Class Labeling Change. FDA 2010:25 mayo. [Ref.ID 88596]
35.Enlace a cita original
Barras MA, Kirkpatrick CMJ, Green B. Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international survey. Br J Clin Pharmacol 2010;69:520-8. [Ref.ID 88442]
36.Tiene citas relacionadas Cita con resumen
Garattini S, Bertele V. Europe's opportunity to open up drug regulation. BMJ 2010;340:842-3. [Ref.ID 88339]
37. Cita con resumen
Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010;362:1 de abril. [Ref.ID 87819]
38. Cita con resumen
Garattini S, Chalmers I. Patients and the public deserve big changes in evaluation of drugs. BMJ 2009;338:804-6. [Ref.ID 87452]
39. Cita con resumen
Anónimo. Uncommon knowledge. Drug Ther Bull 2009;47:121. [Ref.ID 87031]
40. Cita con resumen
Schwartz LM, Woloshin S. Lost in transmission — FDA drug information that never reaches clinicians. N Engl J Med 2009;361:1717-20. [Ref.ID 86923]
Seleccionar todas
 
<< anterior 21 a 40 de 167 siguiente >>